Total Payments
$49,337
2024 Payments
$1,624
Companies
62
Transactions
1,024
Medicare Patients
2,193
Medicare Billing
$273,509
Payment Breakdown by Category
Research$28,955 (58.7%)
Food & Beverage$20,159 (40.9%)
Education$114.13 (0.2%)
Gifts$59.40 (0.1%)
Other$50.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,955 | 3 | 58.7% |
| Food and Beverage | $20,159 | 1,012 | 40.9% |
| Education | $114.13 | 7 | 0.2% |
| Gift | $59.40 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50.00 | 1 | 0.1% |
Payments by Type
Research
$28,955
3 transactions
General
$20,382
1,021 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $28,955 | 3 | $0 (2018) |
| Novo Nordisk Inc | $3,481 | 169 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,074 | 80 | $0 (2022) |
| Lilly USA, LLC | $1,889 | 106 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,754 | 81 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,059 | 50 | $0 (2024) |
| Amgen Inc. | $1,020 | 43 | $0 (2024) |
| Abbott Laboratories | $684.73 | 45 | $0 (2024) |
| Dexcom, Inc. | $621.88 | 29 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $610.85 | 39 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,624 | 79 | Amgen Inc. ($223.22) |
| 2023 | $3,589 | 198 | Novo Nordisk Inc ($541.86) |
| 2022 | $3,008 | 173 | Novo Nordisk Inc ($572.75) |
| 2021 | $2,722 | 160 | Novo Nordisk Inc ($584.71) |
| 2020 | $1,635 | 82 | SANOFI-AVENTIS U.S. LLC ($303.86) |
| 2019 | $2,613 | 99 | AstraZeneca Pharmaceuticals LP ($592.23) |
| 2018 | $9,896 | 136 | AstraZeneca UK Limited ($6,559) |
| 2017 | $24,251 | 97 | AstraZeneca UK Limited ($22,397) |
All Payment Transactions
1,024 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $20.38 | General |
| 12/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Diabetes Care | ||||||
| 12/04/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $24.23 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Cardio-renal | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $2.56 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Automated insulin delivery system | ||||||
| 11/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $101.74 | General |
| Category: Bone Health | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: RESPIRATORY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $27.63 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: Bone Health | ||||||
| 10/02/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/01/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Endocrinology | ||||||
| 09/25/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: Inflammation | ||||||
| 09/24/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart, Flector | Food and Beverage | Cash or cash equivalent | $23.20 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes | AstraZeneca UK Limited | $26,060 | 2 |
| Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes | AstraZeneca UK Limited | $2,896 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 428 | 607 | $225,575 | $64,074 |
| 2022 | 3 | 488 | 644 | $238,849 | $66,799 |
| 2021 | 6 | 644 | 745 | $279,397 | $81,796 |
| 2020 | 6 | 633 | 809 | $213,682 | $60,839 |
Total Patients
2,193
Total Services
2,805
Medicare Billing
$273,509
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 253 | 325 | $141,945 | $39,678 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 161 | 268 | $83,280 | $24,263 | 29.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 14 | 14 | $350.00 | $133.28 | 38.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 252 | 326 | $148,004 | $42,150 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 200 | 281 | $89,920 | $24,293 | 27.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 36 | 37 | $925.00 | $355.79 | 38.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 329 | 376 | $168,094 | $49,013 | 29.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 227 | 280 | $89,445 | $26,728 | 29.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 24 | 24 | $10,138 | $2,976 | 29.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 29 | $6,332 | $1,741 | 27.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $4,763 | $1,096 | 23.0% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 24 | 25 | $625.00 | $242.75 | 38.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 230 | 248 | $91,016 | $26,540 | 29.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 178 | 278 | $75,894 | $20,742 | 27.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 39 | 39 | $16,224 | $4,437 | 27.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 27 | 27 | $14,202 | $4,202 | 29.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 55 | 67 | $12,596 | $3,479 | 27.6% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 104 | 150 | $3,750 | $1,439 | 38.4% |
About Dr. Paul Denker, MD
Dr. Paul Denker, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Palm Harbor, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750328811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Denker, MD has received a total of $49,337 in payments from pharmaceutical and medical device companies, with $1,624 received in 2024. These payments were reported across 1,024 transactions from 62 companies. The most common payment nature is "" ($28,955).
As a Medicare-enrolled provider, Denker has provided services to 2,193 Medicare beneficiaries, totaling 2,805 services with total Medicare billing of $273,509. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Palm Harbor, FL
- Active Since 05/31/2006
- Last Updated 08/27/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1750328811
Products in Payments
- FARXIGA (Drug) $30,818
- Ozempic (Drug) $1,584
- JARDIANCE (Drug) $1,225
- TRULICITY (Drug) $574.19
- TOUJEO (Drug) $562.63
- SOLIQUA 100/33 (Biological) $553.95
- EVENITY (Biological) $511.46
- CYCLOSET (Drug) $504.31
- Rybelsus (Drug) $481.36
- FREESTYLE LIBRE 2 (Device) $473.46
- Tirosint (Drug) $430.68
- AFREZZA (Drug) $430.27
- Omnipod (Device) $417.19
- Korlym (Drug) $404.73
- GVOKE PFS (Drug) $366.02
- HUMULIN (Drug) $326.59
- Tresiba (Drug) $320.24
- Kerendia (Drug) $316.03
- BAQSIMI (Drug) $304.28
- UNITHROID (Drug) $283.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Palm Harbor
Dr. Swati Chalavarya, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $6,142
Endocrinology, Diabetes & Metabolism $6,142
Bianshly Rivera Rivero
Endocrinology, Diabetes & Metabolism — Payments: $2,441
Endocrinology, Diabetes & Metabolism $2,441
Dr. Sanford Plevin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,624
Endocrinology, Diabetes & Metabolism $1,624